These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21604586)

  • 41. EFV/FTC/TDF-associated hepatotoxicity: a case report and review.
    Echenique IA; Rich JD
    AIDS Patient Care STDS; 2013 Sep; 27(9):493-7. PubMed ID: 23937548
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single-tablet, once-daily treatment regimens for HIV.
    Sawyer JR; Ma Q; Hsiao CB
    Lancet Infect Dis; 2014 Apr; 14(4):265-7. PubMed ID: 24670622
    [No Abstract]   [Full Text] [Related]  

  • 43. Symfi, Symfi Lo, and Cimduo for HIV.
    Med Lett Drugs Ther; 2019 Jan; 61(1563):e8-e10. PubMed ID: 30681663
    [No Abstract]   [Full Text] [Related]  

  • 44. [HIV infected women with intense bone and muscular pain and general weakness].
    Pérez-Rivera AÁ; Sáez P; León E; Lozano de León-Naranjo F
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):308-10. PubMed ID: 21334782
    [No Abstract]   [Full Text] [Related]  

  • 45. Early virological failure with a combination of tenofovir, didanosine and efavirenz.
    Podzamczer D; Ferrer E; Gatell JM; Niubo J; Dalmau D; Leon A; Knobel H; Polo C; Iniguez D; Ruiz I
    Antivir Ther; 2005; 10(1):171-7. PubMed ID: 15751775
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
    Martínez E; Larrousse M; Podzamczer D; Pérez I; Gutiérrez F; Loncá M; Barragán P; Deulofeu R; Casamitjana R; Mallolas J; Pich J; Gatell JM;
    AIDS; 2010 Jan; 24(3):F1-9. PubMed ID: 20009917
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination in HIV-1 patients in Fann Teaching Hospital in Dakar].
    Diop SA; Fortes-Déguénonvo L; Seydi M; Dieng AB; Basse CD; Manga NM; Dia NM; Ndaw G; Ndour CT; Soumaré M; Diop BM; Sow PS
    Bull Soc Pathol Exot; 2013 Feb; 106(1):22-6. PubMed ID: 23247755
    [TBL] [Abstract][Full Text] [Related]  

  • 48. FDA paves the way for pre-exposure HIV prophylaxis.
    Holmes D
    Lancet; 2012 Jul; 380(9839):325. PubMed ID: 22852138
    [No Abstract]   [Full Text] [Related]  

  • 49. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
    Gianotti N; Galli L; Bocchiola B; Cahua T; Panzini P; Zandonà D; Salpietro S; Maillard M; Danise A; Pazzi A; Lazzarin A; Castagna A
    HIV Med; 2013 Mar; 14(3):153-60. PubMed ID: 22994659
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimizing initial therapy for HIV infection.
    Hull MW; Montaner JS
    J Infect Dis; 2011 Oct; 204(8):1154-6. PubMed ID: 21917886
    [No Abstract]   [Full Text] [Related]  

  • 52. Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.
    Gupta RK; Wainberg MA; Brun-Vezinet F; Gatell JM; Albert J; Sönnerborg A; Nachega JB
    J Infect Dis; 2013 Jun; 207 Suppl 2(Suppl 2):S101-6. PubMed ID: 23687287
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDA notifications. FDA approves generic combination of efavirenz, lamivudine & tenofovir.
    AIDS Alert; 2009 Nov; 24(11):130. PubMed ID: 19960612
    [No Abstract]   [Full Text] [Related]  

  • 54. [ First integrase inhibitor based single tablet regimen].
    MMW Fortschr Med; 2013 Jun; 155 Suppl 1():20-1. PubMed ID: 23961647
    [No Abstract]   [Full Text] [Related]  

  • 55. Where rilpivirine meets with tenofovir, the start of a new anti-HIV drug combination era.
    De Clercq E
    Biochem Pharmacol; 2012 Aug; 84(3):241-8. PubMed ID: 22504027
    [TBL] [Abstract][Full Text] [Related]  

  • 56. DAART for human immunodeficiency virus-infected patients: Studying subjects not at risk for nonadherence and use of untested interventions.
    Altice FL; Springer SA
    Arch Intern Med; 2010 Jan; 170(1):109-10. PubMed ID: 20065210
    [No Abstract]   [Full Text] [Related]  

  • 57. Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients.
    Labarga P; Medrano J; Seclen E; Poveda E; Rodriguez-Novoa S; Morello J; de Mendoza C; Vispo E; Soriano V
    AIDS; 2010 Mar; 24(5):777-9. PubMed ID: 20168201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk of early virological failure of once-daily tenofovir-emtricitabine plus twice-daily nevirapine in antiretroviral therapy-naive HIV-infected patients.
    Lapadula G; Costarelli S; Quiros-Roldan E; Calabresi A; Izzo I; Carosi G; Torti C
    Clin Infect Dis; 2008 Apr; 46(7):1127-9. PubMed ID: 18444839
    [No Abstract]   [Full Text] [Related]  

  • 59. Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
    Nishijima T; Komatsu H; Teruya K; Tanuma J; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
    AIDS; 2013 Mar; 27(5):839-42. PubMed ID: 23719354
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Impact of antiretroviral dosing frequency and pill burden on adherence among newly diagnosed, antiretroviral-naive HIV patients.
    Buscher A; Hartman C; Kallen MA; Giordano TP
    Int J STD AIDS; 2012 May; 23(5):351-5. PubMed ID: 22648890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.